Pharmaceutical Co.	IND	INN	Proprietary Name	Approved For	Strategy	Index	LRG Trial Report
Novartis	STI-571	imatinib	Gleevec/Glivec	GIST + (CML/ALL/MDS/MPD/ASM/HES/DFSP)	A	5	x
Bristol-Myers Squibb	BMS354825	dasatinib	Sprycel	CML/ALL	A	8	x
Novartis	AMN107	nilotinib	Tasigna		A	10	x
SuperGen	MP371				A	24
Bayer	BAY439006	sorafenib	Nexavar	RCC	B	6	x
Pfizer	SU11248	sunitinib	Sutent	GIST + (RCC)	B	9	x
Novartis	PTK787	vatalanib			B	17	x
Amgen	AMG706				B	18	x
Astra Zeneca	AZD2171		Recentin		B	20	x
OSI	OSI-930				B	25	x
Novartis	PKC412				B	26	x
Novartis	TKI-258				B	27
Exelixis	XL820				B	28	x
Genentech	rhuMAb VEGF	bevacizumab	Avastin	NSCLC/Colorectal	C	1
Kosan Biosciences, Inc.	KOS-1022	alvespimycin			D	13
(multiple)	17DMAG	geldanamycin			D	14
Biogen-Idec	CNF2024				D	21
Infinity	IPI-504				D	22	x
Aventis	HMR1275	alvocidib	Flavopiridol		E	3	x
Novartis	RAD001	everolimus	Certican		F	2	x
Genta	G3139	oblimersen	Genasense		F	4	x
Wyeth	AY 22989	sirolimus/rapamycin	Rapamune	Renal Transplant	F	7
Wyeth	CCI-779	temsirolimus	Torisel		F	11	x
Keryx	KRX-0401	perifosine			F	15	x
Ariad	AP23573				F	19
Merck	SAHA	vorinostat	Zolinza	CTCL	G	12
Gloucester	FR901228	romidepsin			G	16	x
Novartis	LBH589				G	23
IND - Investigational New Drug name
INN; also known as rINN, for recommended International Nonproprietary Name.  Same as generic name.
Proprietary Name - Same as Brand Name
Strategy	Description
A	Inhibit KIT (PDGFRA signaling)
B	Inhibit KIT (PDGFRA signaling) plus Impede tumor vascularization (Antiangiogenesis)
C	Impede tumor vascularization (Antiangiogenesis)
D	Destroy KIT
E	Inhibit the production of KIT
F	Target KIT downstream signaling
G	Destroy KIT plus Inhibit the cell cycle plus Induce apoptosis